TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 961473
Drug: Fructose infusion
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose infusion without amino acids
Study: 27254033
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine
Study: 25100053
Drug: Pill-count data
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill-count data
Study: 31212162
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of oral contraceptives
Study: 18486235
Drug: Venlafaxine 37.5-375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5-375 mg daily
Study: 18486235
Drug: Lithium 300-2100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium 300-2100 mg daily
Study: 17286342
Drug: Broad-spectrum treatment
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum treatment (BST) with naltrexone
Study: 17286342
Drug: Motivational-enhancement therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational-enhancement therapy (MET) with naltrexone
Study: 14712408
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (single injection of Gd‐BOPTA)
Study: 14712408
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (two injections of Gd‐BOPTA)
Study: 10749620
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment (0.3 U/kg/day)
Study: 30716797
Drug: Interval between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval between onset of symptoms and therapy
Study: 9839777
Drug: Teril 600
Normalized name: Teril CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teril 600 CR tablet
Study: 9839777
Drug: Timonil 600
Normalized name: Timonil Retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timonil 600 Retard tablet
Study: 7862232
Drug: Typical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical treatment + ganglioside GM1 (100 mg daily for 30 days, i.v. for first 5 days, then i.m.)
Study: 7862232
Drug: Typical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical treatment + ganglioside GM1
Study: 28940312
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg LSD administered orally
Study: 21633025
Drug: Oral sitamaquine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sitamaquine, 2 mg/kg/day, once a day for 21 days
Study: 21633025
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B (AmB), 1 mg/kg every other day for 30 days
Study: 16923135
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg zinc sulfate three times daily
Study: 16923135
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo tablet three times daily
Study: 16923135
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg zinc sulfate three times daily (after crossover)
Study: 16923135
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo tablet three times daily (after crossover)
Study: 10857970
Drug: Troglitazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (600 mg/day) for 12 weeks
Study: 1440306
Drug: Nitrendipine 40
Normalized name: nitrendipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 40 mg/day
Study: 1440306
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg once or twice a day)
Study: 1440306
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg twice a day
Study: 26762911
Drug: BFD (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFD (standard dose)
Study: 26762911
Drug: BFD-LD (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFD-LD (low dose)
Study: 22999589
Drug: Bronchoscopic argon
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchoscopic argon plasma coagulation plus routine antituberculosis chemotherapy
Study: 22999589
Drug: Routine antituberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antituberculosis chemotherapy
Study: 18254486
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray, 2 sprays per nostril twice daily
Study: 18254486
Drug: Fluticasone nasal
Normalized name: fluticasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal spray, 2 sprays per nostril once daily
Study: 18254486
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azelastine nasal spray and fluticasone nasal spray
Study: 17006062
Drug: Morphine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine administration postoperatively
Study: 8867642
Drug: 3% diclofenac/2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% diclofenac/2.5% sodium hyaluronate topical gel, applied 4 times daily for 2 weeks
Study: 8867642
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel lacking the active substance
Study: 29584458
Drug: Cilnidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine (10 mg/day) for 12 weeks
Study: 16480350
Drug: 10 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg.kg(‐1) methylprednisolone
Study: 11963730
Drug: Heparin during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin during acute therapy of AMI
Study: 11963730
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin during acute therapy of AMI
Study: 11963730
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with fibrinolysis
Study: 11963730
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin with fibrinolysis
Study: 7656462
Drug: Non-insulin-dependent diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-insulin-dependent diabetes mellitus
Study: 2566219
Drug: Histamine injection
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine injection (increasing concentration)
Study: 2566219
Drug: Histamine injection
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine injection (decreasing concentration)
Study: 17503182
Drug: Imipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50 mg)
Study: 827779
Drug: Nomifensine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine (50 mg)
Study: 26810496
Drug: Adjustable, custom-made
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable, custom-made oral appliance (Narval®) without elastic bands
Study: 26810496
Drug: Adjustable, custom-made
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable, custom-made oral appliance (Narval®) with elastic bands
Study: 25209323
Drug: Action 3:30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action 3:30 intervention (40 one-hour sessions, delivered twice a week by teaching assistants)
Study: 17018708
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CHOP-21, CHOP-14)
Study: 12391522
Drug: Face mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face mask with O(2) flow of 15 l/min
Study: 7597662
Drug: Phosphoramidon (10(‐5)
Normalized name: phosphoramidic acid
DrugBank: Phosphoramidon (DB02557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphoramidon (10(‐5) M, 3 ml)
Study: 2205358
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 480 mg/day
Study: 31958907
Drug: Metformin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,000 mg/day)
Study: 30311850
Drug: Internet-facilitated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-facilitated cognitive behavioral therapy (Mom-Net)
Study: 16804289
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with OSAS before CPAP treatment
Study: 3548637
Drug: Clomipramine hydrochloride
Normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine hydrochloride (134 +/- 33 mg/d)
Study: 28864691
Drug: RDN using
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDN using 5F saline‐irrigated radiofrequency ablation (RFA) plus antihypertensive medication
Study: 7477146
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication alone
Study: 11023499
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of MRD at the end of the induction phase (> or = 1%) or at week 14 of continuation therapy (> or = 0.1%)
Study: 8612107
Drug: Ibuprofen (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1800 mg per day)
Study: 6096282
Drug: Glucomannan fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan fiber (1-g doses, two 500 mg capsules with 8 oz water, 1 h prior to each meal)
Study: 29454678
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg CoQ10 daily for 24 weeks
Study: 23293082
Drug: Rituximab +
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab + Dexamethasone (40 mg/day for 4 days and 375 mg/m² weekly for 4 weeks)
Study: 21624649
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (15 days with tapering schedule) plus oral amoxicillin/clavulanate (AMX/C)
Study: 21624649
Drug: Oral amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin/clavulanate (AMX/C) plus placebo
Study: 16456411
Drug: Prepackaged diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepackaged diet kit plus magnesium citrate/bisacodyl laxative (group 1)
Study: 16456411
Drug: Clear liquids
Normalized name: salicylic acid Medicated Liquid Soap [clear days ahead]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear liquids and sodium phosphate solution (group 2)
Study: 11816867
Drug: Mirtazapine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (40 weeks of double-blind continuation-phase therapy)
Study: 11816867
Drug: Placebo (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (40 weeks of double-blind continuation-phase therapy)
Study: 3630598
Drug: Heating humidifier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heating humidifier of inhaled gases
Study: 27594150
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy combined with treatment for ameliorating the PE symptom (oral dapoxetine on-demand and ejaculation control exercise)
Study: 27594150
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (oral administration of antibiotics, α-receptor blocker, and proprietary Chinese medicine)
Study: 23868273
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg intravenously, administered 12 hourly for a total of 5 doses
Study: 20082104
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (Aluminum gallium arsenide laser, 785 nm, 3 J/cm², 70 mW)
Study: 12816140
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) restorations
Study: 11388500
Drug: Nitroderivative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroderivative therapy
Study: 9356879
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg i.v. bolus followed by 300 mg i.v. every 6 hr during hospitalization
Study: 9356879
Drug: Heater probe
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heater probe thermocoagulation + cimetidine 300 mg i.v. bolus followed by 300 mg i.v. every 6 hr during hospitalization
Study: 9356879
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg i.v. bolus followed by 40 mg i.v. daily for two days
Study: 9356879
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg i.v. bolus followed by 40 mg i.v. every 12 h for two days
Study: 8146390
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of mefloquine every month
Study: 8146390
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of mefloquine every two weeks
Study: 8146390
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg sulphadoxine + 25 mg pyrimethamine (Fansidar) a week
Study: 3524176
Drug: Combined probucol
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined probucol (1 g/day) and colestipol (20 g/day)
Study: 3524176
Drug: Modified probucol-colestipol
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Modified probucol-colestipol therapy (half-dose of colestipol)
Study: 3524176
Drug: Combined probucol-colestipol
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined probucol-colestipol therapy after 1 and 3 years
Study: 3524176
Drug: Single-drug administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-drug administration of probucol or colestipol
Study: 30182113
Drug: Lactoferrin (LF)
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin (LF) supplementation, 3 tablets per day (250 mg per tablet) for 30 days
Study: 26813357
Drug: ISA101 vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISA101 vaccination with 5% imiquimod at the vaccine site
Study: 24840349
Drug: Early detection
Normalized name: Leader Early Detection Pregnancy Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early detection and treatment by community health workers using rapid diagnostic technology
Study: 24840349
Drug: Early detection
Normalized name: Leader Early Detection Pregnancy Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early detection and treatment plus larviciding
Study: 23835590
Drug: Intrathecal gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal gabapentin 0 mg/day (placebo)
Study: 23835590
Drug: Intrathecal gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal gabapentin 1 mg/day
Study: 23835590
Drug: Intrathecal gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal gabapentin 6 mg/day
Study: 23835590
Drug: Intrathecal gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal gabapentin 30 mg/day
Study: 23835590
Drug: Intrathecal gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal gabapentin (all doses)
Study: 20455960
Drug: Allogenic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogenic platelet gel
Study: 12536327
Drug: Endoscopic fibrin
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic fibrin glue injection
Study: 10645753
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg tacrolimus
Study: 10645753
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tacrolimus
Study: 8876707
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen blockade (CAB) with zoladex 3.6 mg injection subcutaneous depot monthly and flutamide 250 mg orally three times per day for 2 months, followed by CAB with concurrent XRT (65-70 Gy) for 7-8 weeks
Study: 8876707
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (Z- group)
Study: 1543618
Drug: Temazepam elixir
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Temazepam elixir
Study: 3892975
Drug: Metronidazole (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (9 doses)
Study: 25224018
Drug: PNHA (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNHA (topical gel application two times a week for a total of 6 weeks)
Study: 25224018
Drug: HA (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA (topical application)
Study: 24708617
Drug: Minimal contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal contact web-guided Cognitive Behavioral Therapy (CBT) intervention
Study: 16046715
Drug: High protein,
Normalized name: Ensure High Protein, Banana, Instant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein, reduced carbohydrates diet (1.6 g/(kg . d)) with supervised exercise (5 d/wk walking and 2 d/wk resistance training)
Study: 16046715
Drug: Low protein,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein, high carbohydrates diet (0.8 g/(kg . d)) with supervised exercise (5 d/wk walking and 2 d/wk resistance training)
Study: 16046715
Drug: High protein,
Normalized name: Ensure High Protein, Banana, Instant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein, reduced carbohydrates diet (1.6 g/(kg . d)) with lifestyle activity (control)
Study: 16046715
Drug: Low protein,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein, high carbohydrates diet (0.8 g/(kg . d)) with lifestyle activity (control)
Study: 1712803
Drug: Allergen challenge
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen challenge (single dose sprayed into one side of the nose)
Study: 6227877
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium bromide (40 micrograms/puff) and fenoterol (100 micrograms/puff)
Study: 23569986
Drug: Cisplatin chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin chemotherapy (40-50 mg/day)
Study: 19951955
Drug: Experimental adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental adjuvant treatments
Study: 19951955
Drug: New treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatments for metastatic disease
Study: 17330176
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (ChEI)
Study: 15857723
Drug: Matrix Model
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix Model (manualized treatment)
Study: 12569793
Drug: Chongcao shenkang
Normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chongcao shenkang capsules 2.7 grams tid
Study: 12569793
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (combined therapy with balanced salt solution and ribavirin)
Study: 7475162
Drug: Recombinant aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant aprotinin (dosage level 1: 2 mg/kg bolus, 1 mg/kg in oxygenator prime, 0.5 mg/kg/hr infusion)
Study: 7475162
Drug: Recombinant aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant aprotinin (dosage level 2: doubled doses)
Study: 7475162
Drug: Recombinant aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant aprotinin (dosage level 1)
Study: 7475162
Drug: Recombinant aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant aprotinin (dosage level 2)
Study: 7002430
Drug: Bendroflumethiazide 10
Normalized name: bendroflumethiazide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide 10 mg daily for 3 days
Study: 7002430
Drug: Bendroflumethiazide 10
Normalized name: bendroflumethiazide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide 10 mg daily for 10 weeks
Study: 28060206
Drug: Present Centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present Centered Therapy
Study: 21353329
Drug: Propranolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2 to 2.5 mg/kg per day, divided in 3 doses)
Study: 19378635
Drug: Crossing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossing the border to purchase medications (US residents)
Study: 19378635
Drug: Crossing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossing the border to purchase medications (Ciudad Juarez residents)
Study: 19378635
Drug: Traveling to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traveling to the United States for medications or health care (Mexican nationals)
Study: 15163331
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose hydrocortisone (10 mg twice daily)
Study: 15163331
Drug: Half-dose hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Half-dose hydrocortisone (5 mg twice daily)
Study: 11798229
Drug: Around-the-clock (ATC)
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Around-the-clock (ATC) opioid therapy, specifically controlled-release oral formulations (e.g. morphine, oxycodone, hydromorphone, hydrocodone)